Evaluation of microRNA expression profiles in triple-negative (ER, PR and Her2/neu) breast cancer patients with and without germ-line BRCA mutations

被引：0
|
作者：
Erturk, E. [1 ]
Cecener, G. [2 ]
Egeli, U. [2 ]
Tunca, B. [2 ]
Tezcan, G. [2 ]
Gokgoz, S. [3 ]
Tolunay, S. [4 ]
Tasdelen, I. [3 ]
机构：
[1] Uludag Univ, Vocat Sch Hlth Serv, Bursa, Turkey
[2] Uludag Univ, Fac Med, Dept Med Biol, Bursa, Turkey
[3] Uludag Univ, Fac Med, Dept Gen Surg, Bursa, Turkey
[4] Uludag Univ, Fac Med, Dept Pathol, Bursa, Turkey
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)50355-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
398
引用
收藏
页码：S95 / S95
页数：1
相关论文
共 50 条
  • [31] ER/PR and Her2/Neu Correlation between Immunohistochemisty and Gene Expression Profiling in Women with Invasive Breast Cancer
    Dydo, M.
    Shutter, J.
    LABORATORY INVESTIGATION, 2010, 90 : 44A - 44A
  • [32] QuantiGene 2.0 Assay for ER, PR and HER2 RNA Levels Is a Useful Adjunctive for the Evaluation of ER, PR and HER2 in Breast Cancer
    Lee, A.
    Chae, B. J.
    Song, B. J.
    Jung, S. S.
    Yim, H. W.
    CANCER RESEARCH, 2009, 69 (24) : 758S - 758S
  • [33] Investigation of microRNA expression profiles related tomorphological heterogeneity in triple-negative breast cancer
    Koleckova, M.
    Kolar, Z.
    Ehrmann, J.
    Svoboda, M.
    Slaby, O.
    Bouchal, J.
    Bouchalova, K.
    Janikova, M.
    Srovnal, J.
    Radova, L.
    VIRCHOWS ARCHIV, 2019, 475 : S17 - S17
  • [34] High prevalence of BRCA mutations among Slovenian triple-negative breast cancer patients
    Banjac, M.
    Blatnik, A.
    Strojnik, K.
    Stegel, V.
    Novakovic, S.
    Dragos, V. Setrajcic
    Skerl, P.
    Klancar, G.
    Krajc, M.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1602 - 1602
  • [35] Are patients with triple-negative breast cancer screened for BRCA mutations according to NCCN guidelines?
    Aubry, Staci
    Petersen, Lindsay Floch
    Burgess, Kelly
    Rao, Ruta D.
    Kopkash, Katherine
    Madrigrano, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
  • [36] Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations
    Katherine Clifton
    Angelica Gutierrez-Barrera
    Junsheng Ma
    Roland Bassett
    Jennifer Litton
    Henry Kuerer
    Stacy Moulder
    Constance Albarracin
    Gabriel Hortobagyi
    Banu Arun
    Breast Cancer Research and Treatment, 2018, 170 : 101 - 109
  • [37] Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations
    Clifton, Katherine
    Gutierrez-Barrera, Angelica
    Ma, Junsheng
    Bassett, Roland, Jr.
    Litton, Jennifer
    Kuerer, Henry
    Moulder, Stacy
    Albarracin, Constance
    Hortobagyi, Gabriel
    Arun, Banu
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (01) : 101 - 109
  • [38] Effectiveness of microRNA expressions and PARP inhibitors for triple-negative breast cancer with BRCA1 mutations
    Sasaki, Akiko
    Tsunoda, Yuko
    Tsuji, Mayumi
    Udaka, Yuko
    Oyamada, Hideto
    Oguchi, Katsuji
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2014, 124 : 170P - 170P
  • [39] Response to neoadjuvant chemotherapy among women with triple-negative breast cancer by HER2 expression status
    Budhathoki, Pravash
    Shah, Anish
    Gaire, Suman
    Joshi, Utsav
    Yadav, Siddhartha
    CANCER RESEARCH, 2023, 83 (05)
  • [40] Search for TSG101 germ-line mutations in BRCA1/BRCA2-negative breast/ovarian cancer families
    Hofferbert, S
    Brohm, M
    Weber, BHF
    CANCER GENETICS AND CYTOGENETICS, 1998, 102 (01) : 86 - 87
12345